Passa ai contenuti principali

Sclerosi Multipla: il professor Sclafani (USA) riflette sullo stato della ricerca sulla CCSVI

Articolo del 15 settembre 2013 preso da www.facebook.com



di CCSVI in Multiple Sclerosis (USA) – Joan Beal:

Il professor Salvatore Sclafani è in prima linea nella ricerca sulla CCSVI, nella diagnostica e nel trattamento. Ecco un commento davvero stimolante che ha inserito oggi sul forum ThisIsMS.com. Grazie , Prof. S. apprezziamo il suo continuo impegno. Il prof. Sclafani sarà il principale relatore al convegno sulla CCSVI della NCS a Sherbrooke (Quebec), a fine mese. Non vedo l'ora di conoscerlo e di sentire le suo opinioni.


Dr. Salvatore Sclafani has been at the forefront of CCSVI research, diagnostics and treatment. Here is a truly thought-provoking post he made on the This Is MS.com forum earlier today. Thanks, Dr. S. We appreciate your contnued effort. Dr. Sclafani will be the keynote speaker at the NCS CCSVI conference in Sherbrooke, Quebec later this month. I look forward to meeting him, and hearing his thoughts.
https://www.facebook.com/notes/ncs-the-national-ccsvi-society/dr-sclafani-to-present-the-many-reasons-of-failure-to-improve-or-hold-on-to-impr/611147215572812
++++++++++++++++++++++++++++++


I have been thinking sadly about the loss of the Albany trial. It was such a heroic effort by one man to create a study that would prove whether treatment of CCSVI provided a treatment for MS.


The issues have been distorted to such a great degree that neurologists have elected to negate the entire concept of CCSVI.
the first issue is whether CCSVI causes MS. This issue is irrelevant to me at this point in time. This issue will take years to assess, evaluate, research and conclude.

We have spent three years evaluating whether ultrasound proves an association. In reality what we have tested is whether the technique of ultrasound described by Zamboni is a practical one. The literature suggests that it is not. It requires clear understanding of the concept of interpretation, proper technique needed to validate that concept, and general acceptance of that interpretation. Unfortunately, the ultrasound, while the ultrasound works very well in my practice, is not well reviewed in a variety of peer reviewed papers. Poor correlations have been reported and reproducibility is certainly at question at this point.

The wide variability in results speaks loudly that this is not a good screening test. Most of the randomized studies using ultrasound have really been a test of whether standard jugular ultrasound, or ultrasound done by Zamboni protocol and/or MRI are effective tools of screening. It is clear from the existing literature that Ultrasound requires adherence to a special technique, quite unique and different from standard ultrasound. This makes it a poor screening test. The wide variation in interpretations of ultrasounds in patients with MS indicates that it is not adequate to address the question of whether CCSVI is associated with MS.

We have allowed a suboptimal screening test to take center stage while obvious venographic abnormalities are amply and routinely seen in the peer reviewed literature. These venographic findings, reported in an adequate number of studies, have been largely ignored. The limitations of venography, inherent in a luminal imaging study of an intraluminal disease, only emphasize the degree of significance of these abnormalities. When augmented by an endoluminal imaging study such as intravascular ultrasound, the prevalence of venous abnormalities in patients with MS cannot be rejected.

But proving this association is only of secondary importance. What is most important is that some patients with venous outflow obstructions have symptoms that improve after angioplasty, and at a higher rate than that described for placebos in trials of medications and other therapies. This is the most important thing that we have learned in three years.

It is with deep regret that the entire concept has been politicized, discredited, misunderstood, denigrated, slandered and rejected out of hand. The techniques of treatment, the reasons for recurrence, complications, and failure must be understood in order to discover the role of venous outflow obstruction in neurological conditions. . Why some patients get better must be discovered. Failure to do so, would insult the good memory of Charcot and many others.

The issue here is not about MS, it is about whether venous outflow obstructions can result in neurological symptoms. It is about whether opening venous outflow improves some clinical manifestations often seen in MS.

We need to put MS on the back burner and focus on the symptoms.

s




http://www.thisisms.com/forum/chronic-cerebrospinal-venous-insufficiency-ccsvi-f40/topic10680-7935.html
++++++++++++++++++++++++++++++++


Dr. Sclafani believes that the future of CCSVI depends on education of physicians and patients alike. He is a Founding Member of the International Society for Neurovascular Disease, the primary society dedicated to education and research of CCSVI. His column on THISISMS.COM, DrSclafani Answers Some Questions, has been viewed more than half a million times in the last year by patients and physicians alike. Dr. Sclafani directs the CCSVI Workshops at the annual meetings of the Society of Interventional Radiology.

His research focus is on the development of best practices in preparation for randomized prospective trials. His groundbreaking use of Intravascular Ultrasound (IVUS) since the beginning of his treatments has lead to important break-through in our understanding of the nature of the venous obstructions. He treats patients at American Access Care offices in Brooklyn and Staten Island.
http://www.ccsvicare.org/sclafani.html

Commenti

Post popolari in questo blog

Rebif: reazioni avverse

I pazienti devono essere informati sulle più frequenti reazioni avverse associate alla somministrazione di interferone beta, inclusi i sintomi della sindrome si mil-influenzale (vedere paragrafo 4.8). Questi sintomi sono più evidenti all’inizio della terapia e diminuiscono in frequenza e gravità con il proseguire del trattamento. Rebif deve essere somministrato con cautela ai pazienti con disturbi depressivi pregressi o in corso ed in particolare a quelli con precedenti ideazioni suicide (vedere paragrafo 4.3). È noto che depressione e ideazioni suicide sono presenti con maggior frequenza nella popolazione dei malati di sclerosi multipla ed in associazione con l’uso dell’interferone. I pazienti in trattamento con Rebif devono essere avvisati di riferire immediatamente al loro medico l’eventuale comparsa di sintomi depressivi o ideazioni suicide. I pazienti affetti da depressione devono essere tenuti sotto stretto controllo medico durante la terapia con Rebif e trattati in modo approp

Sclerosi multipla: registro dei farmaci neurologici sottoposti a monitoraggio

Linee Guida 2012 Tysabri clicca qui per scaricare (PDF) Modifiche Gilenya 4 giugno 2012 su Gilenya clicca qui per scaricare (PDF) Nuovi controlli sulla scheda di Eleggibilità/Diagnosi (30 aprile 2012) su Gilenya clicca qui per scaricare (DOC) nota informativa importante del 30 aprile 2012 su Gilenya comunicato stampa Ema Gilenya 30 aprile (PDF) comunicato stampa 23 aprile 2012 comunicato stampa Ema Gilenya (PDF) Avviso modifica scheda Diagnosi Gilenya (fingolimod) del 16/03/2012 Scarica messaggio circolare Nota Informativa Importante su Gilenya (fingolimod) del 30/01/2012 Scarica la nota Comunicato Stampa EMA su Gilenya (fingolimod) del 20/01/2012 - Faq Comunicato Stampa EMA su Gilenya (fingolimod) Comunicato Stampa EMA su Gilenya (fingolimod) del 20/01/2012 - Sicurezza Comunicato Stampa EMA su Gilenya (fingolimod) Comunicazione AIFA del 16/01/2012 sulle schede Gilenya Comunicato schede Gilenya 2 Comunicazione AIFA del 07/12/2011 sulle schede Gilenya Comunicato s

Le complicanze da puntura lombare (rachicentesi)

La rachicentesi è la metodica necessaria per poter eseguire esami diagnostici sul liquor cerebrospinale, cioè il liquido che normalmente circola nel midollo spinale e nel cervello. Tecnicamente consiste nell’introdurre un ago di adeguate dimensioni, circa 10 cm. di lunghezza, nello spazio vertebrale compreso tra le strutture posteriori di una vertebra (le lamine vertebrali) e quelle anteriori, ovvero la superficie posteriore dei corpi vertebrali. Tale è lo spazio peridurale in cui è contenuto il cosiddetto sacco durale che è una propaggine dell’involucro durale che avvolge il midollo spinale. Il sacco durale si prolunga fino alle prime vertebre sacrali, mentre il midollo spinale “si ferma” a livello dell’ultima vertebra dorsale, la 12°. Per tale motivo la puntura del sacco durale per “estrarre” il liquor in esso circolante viene praticata,in genere, tra la 3° e la 4° vertebra lombare. Per motivi che esulano da questa comunicazione, la puntura per il prelievo di liquor può essere f